Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Pediatric Hematology/Oncology|October 2, 2023
Vitamin D Status in Children With High-risk NeuroblastomaAna Carolina Izurieta-Pacheco, Ana Sangrós-Gimenez, Esther Martínez-Garcia, et al.
Cancers|October 16, 2024
Use of Radioguided Surgery for Small and Difficult-to-Locate Relapsed MIBG (+) High-Risk Neuroblastoma LesionsLucas Krauel, Albert Pasten, Maite Gorostegui, et al.
Pediatric Blood & Cancer|May 22, 2021
Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remissionJaume Mora, Alicia Castañeda, Maite Gorostegui, et al.
Frontiers in Pharmacology|December 16, 2020
The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive StudiesJaume Mora, Alicia Castañeda, Miguel A Flores, et al.
Frontiers in Oncology|May 22, 2023
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamabAmalia Varo, Alicia Castañeda, Saray Chamorro, et al.
Pediatric Blood & Cancer|December 6, 2023
SIOP pediatric oncology services Global Mapping Program: Latin American data collectionLuisa Chantada, Maite Gorostegui, Jennifer Lowe, et al.
Frontiers in Oncology|October 13, 2025
Uncovering subclinical cardiotoxicity across chemotherapy phases in pediatric oncologyEsther Aurensanz-Clemente, Patricia Garcia-Canadilla, Maite Gorostegui, et al.
Cancers|October 14, 2023
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term OutcomesJuan Pablo Muñoz, Cristina Larrosa, Saray Chamorro, et al.
Cancers|May 11, 2024
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 ImmunotherapyMaite Gorostegui, Juan Pablo Muñoz, Sara Perez-Jaume, et al.
Cancers|May 13, 2023
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome ReportJaume Mora, Alicia Castañeda, Maite Gorostegui, et al.
Pageof 2